IDXG on OTC

INTERPACE BIOSCIENCES, INC.

Clinical services that help guide patient management decisions by providing information on the diagnosis and prognosis of indeterminate specimens.³ From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with UTAH MEDICAL PRODUCTS INC, RETRACTABLE TECHNOLOGIES INC or Cytosorbents, or pick any stock.

TickerIDXG on OTC¹
IndustrySurgical & Medical Instruments & Apparatus¹
HeadquartersParsippany, New Jersey¹
Incorporated inDE²
Business addressWaterview Plaza, Suite 310, 2001 Route 46, Parsippany, Nj 07054²
Filer categoryNon-accelerated filer, Smaller reporting company²
Legal formCorporation

See how the biggest companies compare on our leaderboards

Clinical services that help guide patient management decisions by providing information on the diagnosis and prognosis of indeterminate specimens. Guidance on genetic marker-related pharmaceutical treatment options, when available, is also provided.³ From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

62.3%Gross margin⁴

10.5%Operating margin⁴

63.5%Net margin⁴

-17.5%Revenue growth, 2025⁴

109.9%Return on equity⁴

$5.5MFree cash flow⁴

Where the money goes

Where each dollar of revenue went, fiscal 2025

Cost of revenueIncome taxProfit

Cost of revenue24¢$14.6M
Research and development1¢$642.0K
Income tax35¢$21.2M
Profit40¢$24.6M

Out of $38.7M in revenue.⁴

Where each dollar of operating cash went, fiscal 2025

Kept or used elsewhere

Capital spending6¢$356.0K
Kept or used elsewhere94¢$5.5M

Out of $5.8M of cash from operations.⁴

Financial statements

Revenue⁵⁶⁷⁸⁹⁴$38.7M in 2025+60% since 2019

Gross profit⁵⁶⁷⁸⁹⁴$24.1M in 2025+190% since 2019

Operating income⁵⁶⁷⁸⁹⁴$4.1M in 2025

Net income⁵⁶⁷⁸⁹⁴$24.6M in 2025

Every line of the income statement as filed: the last 2 fiscal years, latest first.⁴

Period ending	2025-12-31	2024-12-31
Revenue, net	$38.7M	$46.9M
Cost of revenue	$14.6M	$17.0M
Gross profit	$24.1M	$29.9M
Sales and marketing	$9.9M	$11.7M
Research and development	$642.0K	$676.0K
General and administrative	$9.5M	$9.5M
Total operating expenses	$20.0M	$21.8M
Operating income from continuing operations	$4.1M	$8.1M
Interest accretion expense		-$34.0K
Note payable interest expense	-$168.0K	-$625.0K
Other expense, net	-$142.0K	-$499.0K
Income from continuing operations before tax	$3.8M	$7.0M
(Benefit) provision for income taxes	-$21.2M	$4.0K
Income from continuing operations	$25.0M	$6.9M
Loss from discontinued operations, net of tax	-$409.0K	-$244.0K
Net income	$24.6M	$6.7M
Less adjustment for preferred stock deemed dividend		-$464.0K
Net income attributable to common stockholders	$24.6M	$6.2M
From continuing operations	$6	$1
From discontinued operations	-$0	-$0
Net income (loss) per basic share of common stock	$5.55	$1.42
From continuing operations	$1	$0
From discontinued operations	-$0	-$0
Net income (loss) per diluted share of common stock	$0.89	$0.40
Basic	4.4M shares	4.4M shares
Diluted	27.7M shares	15.7M shares

Total assets⁵⁶⁷⁸⁹⁴$33.8M in 2025−34% since 2019

Total liabilities⁵⁶⁷⁸⁹⁴$11.5M in 2025−62% since 2019

Shareholders’ equity⁵⁷⁸⁹⁴$22.4M in 2025

Cash⁵⁶⁷⁸⁹⁴$2.5M in 2025+8% since 2019

Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.⁴

Period ending	2025-12-31	2024-12-31	2023-12-31	2021-02-28
Cash and cash equivalents	$2.5M	$1.5M
Accounts receivable	$5.6M	$8.5M
Other current assets	$1.7M	$1.8M
Total current assets	$9.9M	$11.8M
Property and equipment, net	$1.4M	$1.4M
Operating lease right of use assets	$1.2M	$1.6M
Deferred tax asset	$21.3M
Other long-term assets	$44.0K	$45.0K
Total assets	$33.8M	$14.8M
Accounts payable	$983.0K	$1.7M
Accrued salary and bonus	$1.9M	$2.2M
Other accrued expenses	$1.6M	$1.8M
Note payable at fair value, current		$4.3M
Current liabilities of discontinued operations	$660.0K	$660.0K
Total current liabilities	$5.1M	$10.6M
Operating lease liabilities, net of current portion	$752.0K	$1.2M
Other long-term liabilities	$5.6M	$5.2M
Total liabilities	$11.5M	$17.0M
Common stock, $.01 par value; 100,000,000 shares authorized; 4,569,333 and 4,539,663 shares issued, respectively; 4,428,539 and 4,409,323 shares outstanding, respectively	$407.0K	$406.0K
Additional paid-in capital	$234.8M	$234.8M
Accumulated deficit	-$210.8M	-$235.4M
Treasury stock, at cost (140,794 and 130,340 shares, respectively)	-$2.1M	-$2.1M
Total stockholders equity (deficit)	$22.4M	-$2.2M	-$55.5M
Total liabilities and stockholders equity (deficit)	$33.8M	$14.8M
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	5.0M shares	5.0M shares
Common stock, par value	$0.01	$0.01		$0.01
Common stock, shares authorized	100.0M shares	100.0M shares
Common stock, shares issued	4.6M shares	4.5M shares
Common stock, shares outstanding	4.4M shares	4.4M shares
Treasury stock, shares	140.8K shares	130.3K shares

Period ending	2025-12-31	2024-12-31	2023-12-31	2021-02-28
Cash and cash equivalents	$2.5M	$1.5M
Accounts receivable	$5.6M	$8.5M
Other current assets	$1.7M	$1.8M
Total current assets	$9.9M	$11.8M
Property and equipment, net	$1.4M	$1.4M
Operating lease right of use assets	$1.2M	$1.6M
Deferred tax asset	$21.3M
Other long-term assets	$44.0K	$45.0K
Total assets	$33.8M	$14.8M
Accounts payable	$983.0K	$1.7M
Accrued salary and bonus	$1.9M	$2.2M
Other accrued expenses	$1.6M	$1.8M
Note payable at fair value, current		$4.3M
Current liabilities of discontinued operations	$660.0K	$660.0K
Total current liabilities	$5.1M	$10.6M
Operating lease liabilities, net of current portion	$752.0K	$1.2M
Other long-term liabilities	$5.6M	$5.2M
Total liabilities	$11.5M	$17.0M
Common stock, $.01 par value; 100,000,000 shares authorized; 4,569,333 and 4,539,663 shares issued, respectively; 4,428,539 and 4,409,323 shares outstanding, respectively	$407.0K	$406.0K
Additional paid-in capital	$234.8M	$234.8M
Accumulated deficit	-$210.8M	-$235.4M
Treasury stock, at cost (140,794 and 130,340 shares, respectively)	-$2.1M	-$2.1M
Total stockholders equity (deficit)	$22.4M	-$2.2M	-$55.5M
Total liabilities and stockholders equity (deficit)	$33.8M	$14.8M
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	5.0M shares	5.0M shares
Common stock, par value	$0.01	$0.01		$0.01
Common stock, shares authorized	100.0M shares	100.0M shares
Common stock, shares issued	4.6M shares	4.5M shares
Common stock, shares outstanding	4.4M shares	4.4M shares
Treasury stock, shares	140.8K shares	130.3K shares

Cash from operations⁵⁶⁷⁸⁹⁴$5.8M in 2025

Capital spending⁵⁶⁷⁸⁹⁴$356.0K in 2025+172% since 2019

Free cash flow⁵⁶⁷⁸⁹⁴$5.5M in 2025

Every line of the cash flow as filed: the last 2 fiscal years, latest first.⁴

Period ending	2025-12-31	2024-12-31
Net income	$24.6M	$6.7M
Depreciation and amortization	$425.0K	$300.0K
Interest accretion expense		$34.0K
Asset impairment - lab supplies	$198.0K
Amortization of deferred financing fees	$58.0K
Stock-based compensation	$35.0K	$291.0K
Amortization on operating lease right of use asset	$396.0K	$448.0K
Deferred taxes	-$21.3M
Change in fair value of note payable	$110.0K	$547.0K
Accounts receivable	$2.9M	-$3.5M
Other current assets	-$234.0K	$73.0K
Other long-term assets	$1.0K
Accounts payable	-$807.0K	$120.0K
Accrued salaries and bonus	-$321.0K	$238.0K
Accrued liabilities	-$273.0K	-$404.0K
Operating lease liabilities	-$382.0K	-$480.0K
Long-term liabilities	$409.0K	$243.0K
Net cash provided by operating activities	$5.8M	$4.6M
Purchase of property and equipment	-$356.0K	-$876.0K
Net cash used in investing activities	-$356.0K	-$876.0K
Payments made on note payable	-$4.4M	-$5.6M
Series C conversion costs	-$13.0K	-$161.0K
Cash paid for repurchase of restricted shares	-$18.0K	-$46.0K
Net cash used in financing activities	-$4.4M	-$5.8M
Net increase (decrease) in cash and cash equivalents	$1.0M	-$2.0M

Compare INTERPACE BIOSCIENCES, INC. with another company

Leadership

Who has led INTERPACE BIOSCIENCES, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive officerThomas W. Burnell Dec 2, 2020 to now¹³
Chief executive officerJack E. Stover Feb 5, 2016 to Apr 6, 2020¹⁴
Chief executive officerRobert Owen Likoff Nov 16, 2010 to Nov 16, 2010¹⁵
Chief executive officerNancy Lurker Nov 24, 2008 to Mar 9, 2015¹⁶
Chief executive officerMichael Marquard May 22, 2006 to Jun 13, 2008¹⁷
ChairThomas W. Burnell Aug 20, 2026 to now¹⁸
PresidentThomas W. Burnell Dec 2, 2020 to now¹³
PresidentJack E. Stover Feb 5, 2016 to Apr 6, 2020¹⁴
PresidentGerald R. Melillo Jr. Apr 8, 2013 to Dec 4, 2015¹⁹
PresidentHoward Drazner Apr 10, 2009 to Nov 18, 2010²⁰
PresidentPeter Tilles Apr 20, 2009 to Apr 20, 2009²¹
PresidentStephen Cotugno Aug 29, 2006 to Aug 29, 2006²²
PresidentSteven K. Budd Aug 29, 2006 to Aug 29, 2006²³
PresidentKevin Connolly Sep 21, 2006 to Sep 21, 2006²⁴
Chief financial officerThomas John Freeburg Mar 12, 2021 to Mar 12, 2021²⁵
Chief financial officerFred S. Knechtel Feb 3, 2020 to Feb 3, 2020²⁶
Chief financial officerNat Krishnamurti Mar 3, 2016 to Mar 3, 2016²⁷
Chief financial officerJames Early Oct 19, 2016 to Jan 31, 2020²⁸
Chief financial officerGraham G. Miao Oct 22, 2014 to Dec 30, 2015²⁹
Chief financial officerJames G. Farrell Jun 30, 2008 to Aug 21, 2008³⁰

Board members and other officers (32)

Chief Accounting OfficerThomas John Freeburg Apr 11, 2018 to Mar 15, 2019³¹
PDI SVP IT, GM GROUP DCAJo Ann Saitta Feb 9, 2012 to Mar 5, 2013³²
SVP, Business DevelopmentGerald R. Melillo Jr. Oct 13, 2011 to Feb 1, 2012³³
SVP,Bus. Dev Medical EducationHoward Drazner Dec 1, 2010 to Dec 1, 2010³⁴
Senior VP, Sales ServicesRichard P. Micali Apr 23, 2009 to Mar 7, 2011³⁵
Senior VP Business DevelopmentDavid E. Kerr Jun 12, 2009 to Mar 7, 2011³⁶
VP, Corporate ControllerJames G. Farrell Nov 19, 2008 to Nov 19, 2008³⁷
EVP, Marketing ServicesKevin Connolly Apr 3, 2007 to Jun 30, 2008³⁸
Former Exec VP & GCBeth Jacobson Mar 14, 2006 to Mar 14, 2006³⁹
EVP, Human ResourcesNancy McCarthy Aug 24, 2006 to Jun 30, 2008⁴⁰
Board memberVijay Aggarwal Feb 2, 2022 to now⁴¹
Board memberFortunato R. Rocca Jan 28, 2020 to now⁴²
Board memberThomas W. Burnell Dec 2, 2020 to May 25, 2021¹³
Board memberEric B. Lev Jul 25, 2019 to Jan 17, 2020⁴³
Board memberLaurence McCarthy Oct 28, 2019 to Jan 17, 2020⁴⁴
Board memberRobert J. Gorman Oct 28, 2019 to Feb 2, 2021⁴⁵
Board memberFelice Schnoll-Sussman Sep 21, 2017 to Mar 9, 2018⁴⁶
Board memberHarry Glorikian Jan 7, 2016 to Feb 5, 2016⁴⁷
Board memberJoseph D. Keegan Jan 7, 2016 to now⁴⁸
Board memberKapila Ratnam Nov 5, 2015 to Nov 5, 2015⁴⁹
Board memberHeiner Dreismann Aug 15, 2014 to Jun 4, 2015⁵⁰
Board memberNancy Lurker Nov 7, 2014 to Mar 9, 2015⁵¹
Board memberJohn M. Climaco Nov 4, 2013 to Jun 5, 2014⁵²
Board memberGerald P. Belle May 1, 2008 to Jun 11, 2015⁵³
Board memberVeronica Lubatkin Nov 25, 2008 to Jun 6, 2013⁵⁴
Board memberFrank J. Ryan Jun 8, 2006 to Jun 2, 2011⁵⁵
Board memberJan Martens Vecsi Jun 8, 2006 to Jun 7, 2010⁵⁶
Board memberJohn Federspiel Jun 8, 2006 to Jun 4, 2015⁵⁷
Board memberJohn M. Pietruski Jun 8, 2006 to Jun 8, 2009⁵⁸
Board memberJoseph I. Curti Jun 8, 2006 to Jun 8, 2009⁵⁹
Board memberStephen J. Sullivan Jun 8, 2006 to now⁶⁰
Board memberJack E. Stover Aug 31, 2006 to Apr 6, 2020⁶¹

Named in SEC Form D filings

People the company listed in its private-offering notices.

Chief Financial OfficerChristopher W. McCarthy named Oct 16, 2024⁶²

Former names

Interpace Diagnostics Group, Inc.Dec 23, 2015 to Nov 1, 2019²
PDI INCNov 14, 2002 to Dec 22, 2015²
PROFESSIONAL DETAILING INCMay 13, 1998 to Nov 13, 2002²

Timeline

Dec 2, 2020New chief executive Thomas W. Burnell becomes CEO¹³
Feb 5, 2016New chief executive Jack E. Stover becomes CEO¹⁴
Nov 16, 2010New chief executive Robert Owen Likoff becomes CEO¹⁵
Nov 24, 2008New chief executive Nancy Lurker becomes CEO¹⁶
May 22, 2006New chief executive Michael Marquard becomes CEO¹⁷

Filings

128 filings to the SEC since October 2021: 10 annual reports, 15 quarterly reports, 49 major events, 16 insider forms, 12 large holders, 1 private raises, 25 other. The latest 20:

Oct 15, 2026FWP EDGAR
Oct 15, 20268-K EDGAR
Oct 1, 2026S-1/A EDGAR
Sep 25, 2026S-1 EDGAR
Sep 17, 2026S-8 EDGAR
Aug 27, 20268-K EDGAR
Aug 26, 20268-K/A EDGAR
Aug 21, 20268-K EDGAR
Aug 20, 20264 EDGAR
Aug 20, 20264 EDGAR
Aug 20, 20264 EDGAR
Aug 20, 20264 EDGAR
Aug 20, 20264 EDGAR
Aug 20, 20264 EDGAR
Aug 12, 20268-K EDGAR
Aug 10, 202610-Q EDGAR
Jul 22, 2026DRS EDGAR
Jul 7, 2026DEFA14A EDGAR
Jul 7, 2026DEF 14A EDGAR
Jun 25, 2026PREM14A EDGAR

The 128 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Douglas Mark SingerSCHEDULE 13G/A, 5 filings Feb 10, 2022 to Feb 14, 2025⁶³
1315 Capital II, L.P.SC 13D/A, 2 filings Nov 12, 2021 to Oct 16, 2024⁶⁴
Ampersand 2018 Limited PartnershipSC 13D/A, 2 filings Nov 12, 2021 to Oct 16, 2024⁶⁵
Peter H. KaminSC 13D/A, 3 filings Dec 6, 2021 to Feb 1, 2022⁶⁶

Money raised

Private offerings the company reported to the SEC on Form D.

Oct 11, 2024Raised $47 million in a private offering of equity Form D: 2 investors so far Form D

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARINTERPACE BIOSCIENCES, INC. filings on SEC EDGAR
2
SEC EDGARINTERPACE BIOSCIENCES, INC. filings on SEC EDGAR
3
SEC EDGARINTERPACE BIOSCIENCES, INC. annual report, Item 1 (Business)
4
SEC EDGARINTERPACE BIOSCIENCES, INC. 10-K for fiscal 2025
5
SEC EDGARINTERPACE BIOSCIENCES, INC. 10-K for fiscal 2019
6
SEC EDGARINTERPACE BIOSCIENCES, INC. 10-K for fiscal 2020
7
SEC EDGARINTERPACE BIOSCIENCES, INC. 10-K for fiscal 2021
8
SEC EDGARINTERPACE BIOSCIENCES, INC. 10-K for fiscal 2022
9
SEC EDGARINTERPACE BIOSCIENCES, INC. 10-K for fiscal 2023
10
SEC EDGARINTERPACE BIOSCIENCES, INC. 10-Q for fiscal 2026
11
SEC EDGARINTERPACE BIOSCIENCES, INC. 10-Q for fiscal 2026
12
SEC EDGARINTERPACE BIOSCIENCES, INC. 10-Q for fiscal 2025
13
SEC EDGARThomas W. Burnell, Chief executive officer
14
SEC EDGARJack E. Stover, Chief executive officer
15
SEC EDGARRobert Owen Likoff, Chief executive officer
16
SEC EDGARNancy Lurker, Chief executive officer
17
SEC EDGARMichael Marquard, Chief executive officer
18
SEC EDGARThomas W. Burnell, Chair
19
SEC EDGARGerald R. Melillo Jr., President
20
SEC EDGARHoward Drazner, President
21
SEC EDGARPeter Tilles, President
22
SEC EDGARStephen Cotugno, President
23
SEC EDGARSteven K. Budd, President
24
SEC EDGARKevin Connolly, President
25
SEC EDGARThomas John Freeburg, Chief financial officer
26
SEC EDGARFred S. Knechtel, Chief financial officer
27
SEC EDGARNat Krishnamurti, Chief financial officer
28
SEC EDGARJames Early, Chief financial officer
29
SEC EDGARGraham G. Miao, Chief financial officer
30
SEC EDGARJames G. Farrell, Chief financial officer
31
SEC EDGARThomas John Freeburg, Chief Accounting Officer
32
SEC EDGARJo Ann Saitta, PDI SVP IT, GM GROUP DCA
33
SEC EDGARGerald R. Melillo Jr., SVP, Business Development
34
SEC EDGARHoward Drazner, SVP,Bus. Dev Medical Education
35
SEC EDGARRichard P. Micali, Senior VP, Sales Services
36
SEC EDGARDavid E. Kerr, Senior VP Business Development
37
SEC EDGARJames G. Farrell, VP, Corporate Controller
38
SEC EDGARKevin Connolly, EVP, Marketing Services
39
SEC EDGARBeth Jacobson, Former Exec VP & GC
40
SEC EDGARNancy McCarthy, EVP, Human Resources
41
SEC EDGARVijay Aggarwal, Board member
42
SEC EDGARFortunato R. Rocca, Board member
43
SEC EDGAREric B. Lev, Board member
44
SEC EDGARLaurence McCarthy, Board member
45
SEC EDGARRobert J. Gorman, Board member
46
SEC EDGARFelice Schnoll-Sussman, Board member
47
SEC EDGARHarry Glorikian, Board member
48
SEC EDGARJoseph D. Keegan, Board member
49
SEC EDGARKapila Ratnam, Board member
50
SEC EDGARHeiner Dreismann, Board member
51
SEC EDGARNancy Lurker, Board member
52
SEC EDGARJohn M. Climaco, Board member
53
SEC EDGARGerald P. Belle, Board member
54
SEC EDGARVeronica Lubatkin, Board member
55
SEC EDGARFrank J. Ryan, Board member
56
SEC EDGARJan Martens Vecsi, Board member
57
SEC EDGARJohn Federspiel, Board member
58
SEC EDGARJohn M. Pietruski, Board member
59
SEC EDGARJoseph I. Curti, Board member
60
SEC EDGARStephen J. Sullivan, Board member
61
SEC EDGARJack E. Stover, Board member
62
SEC EDGARINTERPACE BIOSCIENCES, INC. Form D naming Christopher W. McCarthy
63
SEC EDGARDouglas Mark Singer SCHEDULE 13G/A on INTERPACE BIOSCIENCES, INC.
64
SEC EDGAR1315 Capital II, L.P. SC 13D/A on INTERPACE BIOSCIENCES, INC.
65
SEC EDGARAmpersand 2018 Limited Partnership SC 13D/A on INTERPACE BIOSCIENCES, INC.
66
SEC EDGARPeter H. Kamin SC 13D/A on INTERPACE BIOSCIENCES, INC.